


**Table.** Base case model results

	<b>Atezolizumab (intervention)</b>	<b>BSC (comparator)</b>	<b>Absolute difference</b>
DFS	\$131,179.61	\$941.49	\$130,238.12
Locoregional recurrence (curative)	\$7,666.68	\$8,838.79	-\$1,172.11
Locoregional recurrence (palliative)	\$1,826.87	\$3,156.90	-\$1,330.03

	<b>Atezolizumab (intervention)</b>	<b>BSC (comparator)</b>	<b>Absolute difference</b>
Metastatic recurrence (1L)	\$54,154.64	\$77,888.86	-\$23,734.22
Metastatic recurrence (2L)	\$71,501.69	\$101,228.50	-\$29,726.81
<b>Total costs</b>	<b>\$292,491.84</b>	<b>\$227,671.57</b>	<b>\$64,820.27</b>
Total LYs	9.27	7.87	1.41
<b>Total QALYs</b>	<b>6.83</b>	<b>5.78</b>	<b>1.06</b>
Cost per LY	Atezolizumab vs BSC: \$46,070		
<b>Cost per QALY (ICER)</b>	<b>Atezolizumab vs BSC: \$61,454</b>		

LY, life-year; QALY, quality-adjusted life-year.

Figure. Cost-effectiveness acceptability curve



**New data since the time of original submission that has been reflected in the original poster:**

Based on the latest estimates of model inputs, atezolizumab is associated with an incremental cost of \$48,956 and incremental QALYs of 1.045, leading to an updated ICER of \$46,859 per QALY. Atezolizumab remained cost-effective in 91% of iterations at the WTP threshold of \$150,000.